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Ekaterina I. Biterova and Joseph J. Barycki1
From the Department of Biochemistry and the Redox Biology Center, University of Nebraska, Lincoln, Nebraska 68588
Structural characterization of glutamate cysteine ligase (GCL),
the enzyme that catalyzes the initial, rate-limiting step in glutathione biosynthesis, has revealed many of the molecular details
of substrate recognition. To further delineate the mechanistic
details of this critical enzyme, we have determined the structures of two inhibited forms of Saccharomyces cerevisiae GCL
(ScGCL), which shares significant sequence identity with the
human enzyme. In vivo, GCL activity is feedback regulated by
glutathione. Examination of the structure of ScGCL-glutathione
complex (2.5 Å; R ⴝ 19.9%, Rfree ⴝ 25.1%) indicates that the
inhibitor occupies both the glutamate- and the presumed cysteine-binding site and disrupts the previously observed Mg2ⴙ
coordination in the ATP-binding site. L-Buthionine-S-sulfoximine (BSO) is a mechanism-based inhibitor of GCL and has
been used extensively to deplete glutathione in cell culture
and in vivo model systems. Inspection of the ScGCL-BSO
structure (2.2 Å; R ⴝ 18.1%, Rfree ⴝ 23.9%) confirms that BSO
is phosphorylated on the sulfoximine nitrogen to generate
the inhibitory species and reveals contacts that likely contribute to transition state stabilization. Overall, these structures
advance our understanding of the molecular regulation of
this critical enzyme and provide additional details of the catalytic mechanism of the enzyme.

Glutamate cysteine ligase (GCL)2 catalyzes the initial and
rate-limiting step of glutathione biosynthesis (1, 2). The ATPdependent mechanism proceeds via a ␥-glutamylphosphate
intermediate (2– 4), with a subsequent nucleophilic attack by
the ␣-amino group of L-cysteine to produce ␥-glutamylcysteine
(1, 2). There are three distinct families of GCL enzymes: ␥-proteobacteria (Group 1), nonplant eukaryotes (Group 2), and
␣-proteobacteria and plants (Group 3) (5). Despite low sequence conservation between these groups (typically ⬍10%
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sequence identity), all of the GCL appear to use this general
catalytic mechanism. The resulting ␥-glutamylcysteine is coupled to L-glycine by glutathione synthetase (1) in an analogous
reaction to generate reduced GSH, an abundant cellular reducing agent.
GCL activity is tightly modulated by free L-cysteine availability (6), transcriptional regulation (7), and post-translational
modifications (8). In addition, GCL is feedback regulated by the
end product, glutathione (9). Glutathione inhibits GCL competitively with respect to L-glutamate, suggesting that the two
binding sites are coincident (9). In heterodimeric GCL, such as
the Drosophila, rat, and human enzymes, binding of the modifier subunit relieves feedback inhibition both by increasing the
Ki for glutathione and decreasing the Km for glutamate (10 –13).
Further studies with glutathione analogues such as ophthalmic
acid, S-methylglutathione, and GSSG have demonstrated that
the free thiol group of glutathione is necessary for maximal
inhibition (1, 9). However, the precise mode of glutathione
binding has not been described.
The central role of GCL in glutathione homeostasis makes
it an attractive target for drug design. Increased glutamate
cysteine ligase catalytic subunit mRNA levels and GCL activity have been frequently observed in cells derived from human
tumors resistant to chemotherapeutic agents (14 –16). Increased production of glutathione likely protects against reactive oxygen and nitrogen species (17, 18) and facilitates detoxification of electrophilic xenobiotics by the glutathione
S-transferases (19). Drug resistance in tumors can be overcome
by the administration of L-buthionine-S,R-sulfoximine (BSO)
(20), which inhibits GCL and subsequently depletes GSH, thus
sensitizing the cancer cells to radiation treatment and chemotherapy. Administration of BSO has also been shown to prolong
the survival of mice infected with the parasite Trypanosoma
brucei (21), the causative agent of African sleeping sickness.
Similarly, BSO-mediated depletion of glutathione inhibits the
development Plasmodium falciparum in red blood cells (22).
BSO presumably binds as an L-glutamate analogue with its
S-butyl group extending into the L-cysteine-binding site (23).
Subsequent ATP-dependent phosphorylation of the sulfoximine nitrogen by GCL leads to the formation of a tightly bound
transition state analogue (20, 23).
Recently, we reported the crystal structure of Saccharomyces
cerevisiae GCL (ScGCL) in complex with L-glutamate, Mg2⫹,
and ADP (24). As the first structure of a Group 2 glutamate
cysteine ligase, examination of the model provided important
molecular details of substrate recognition and led to the identification of key catalytic residues. In the current study, we have
determined the crystal structures of two inhibited forms of the
JOURNAL OF BIOLOGICAL CHEMISTRY
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enzyme. The structure of ScGCL in complex with glutathione
reveals the molecular details of feedback inhibition, whereas
the ScGCL-BSO complex structure details the mechanism of
BSO inhibition. Examination of the available ScGCL structures
provides considerable insight in the catalytic mechanism of the
enzyme and suggests approaches by which GCL inhibitors with
greater selectivity may be attainable.

TABLE 1
Apparent kinetic constants for wild-type ScGCL

EXPERIMENTAL PROCEDURES

Crystallization, Data Collection, Structure Determination,
and Refinement—Concentrated ScGCL (7 mg/ml) was crystallized in the presence of either 5 mM reduced glutathione and 20
mM MgCl2 or 1 mM BSO, 5 mM ATP, and 20 mM MgCl2. Crystals were grown at 18 °C out of a solution of 12% (w/v) polyethylene glycol 400, 100 mM MES, pH 6.8, with the dimensions
0.15 ⫻ 0.15 ⫻ 0.15 mm, as described previously (24). Prior to
data collection, the crystals were soaked in a stabilizing solution
containing 30% polyethylene glycol 400 and the appropriate
ligands and then vitrified in liquid nitrogen (26). Diffraction
data for the ScGCL-glutathione complex were collected using
radiation produced by a Rigaku MicroMax-007 x-ray generator
fitted with confocal blue optics and an R-axis IV⫹⫹ image plate
system ( ⫽ 1.54 Å; 100 K). For the ScGCL-BSO complex, diffraction data ( ⫽ 0.9 Å; 100 K) were collected on Beamline
14-BM-C of BioCARS at Argonne National Laboratory Advanced Photon Source. All of the data were processed with the
HKL2000 software package (27). The structures of the ScGCL
complexes were determined by molecular replacement using
the PHENIX software suite (28) with the previously determined
ScGCL structure (Protein Data Bank code 3IG5) as the search
model. Iterative rounds of model building and refinement were
carried out using Coot (29) and Refmac5 (30), respectively. As
the protein models neared completion, water molecules obeying proper hydrogen-bonding constraints with electron density
greater than 1.0  on a 2Fo ⫺ Fc map and 4.0  on an Fo ⫺ Fc
map were also included in the final structure. Model geometry
was monitored using MOLPROBITY (31), and the figures were
produced using Chimera (32).

Protein Expression and Purification—ScGCL was expressed
in Escherichia coli RosettaTM2(DE3) pLysS cells (Novagen) and
purified to homogeneity as described previously (24). Briefly,
soluble cell lysates were cleared of debris by centrifugation and
ScGCL isolated by affinity chromatography using a HisTrap
Chelating HP Column (GE Healthcare). The protein was further
purified by size exclusion chromatography using a Sephacryl 200
gel filtration column. Purified ScGCL was dialyzed against 20
mM Tris-HCl, pH 7.4, 2 mM dithiothreitol, concentrated (Amicon stirred cell 8050, 10-kDa cut-off), flash-frozen in liquid
nitrogen, and stored at ⫺80 °C. Point mutations were introduced at residue Cys266 (C266S and C266A) by using the
QuikChange site-directed mutagenesis kit (Stratagene) following the manufacturer’s protocol. All of the constructs were verified by sequencing at the University of Nebraska Genomics
Facility (Lincoln, NE).
Kinetic Assays—Enzymatic activity was measured using an
indirect assay that couples ADP production to NADH oxidation, which was monitored at 340 nm (11). The reaction mixture contained 20 mM MgCl2, 5 mM phosphoenolpyruvic acid,
0.2 mM NADH, and 4 units each of pyruvate kinase and lactate
dehydrogenase in 1 ml of buffer (100 mM Tris, pH 8.0, 150 mM
KCl). The reaction was initiated by the addition of ScGCL. To
determine the apparent Km values, two of the three substrates
were added to the reaction at a saturating concentration (20 mM
L-glutamate, 10 mM L-cysteine, 5 mM ATP), whereas the third
was varied. At high concentrations of cysteine or ATP, substrate inhibition was observed.
To examine the mode of inhibition of glutathione, the rates
for the enzyme-catalyzed reaction as a function of glutamate
concentration were determined in the presence of fixed concentrations of glutathione (0, 2.5, and 5.0 mM). A general mixed
model of inhibition was initially selected in Prism (Graph Pad
Software) to describe the dependence of rate versus substrate
concentration. This global analysis indicated that glutathione
was a competitive inhibitor with respect to glutamate. Following this preliminary analysis, the data were reanalyzed designating competitive inhibition (supplemental Fig. S1). For inactivation studies, ScGCL (1.75 M) was incubated with BSO (Sigma)
in 100 mM Tris, pH 8.0, containing 150 mM KCl, 20 mM MgCl2,
and 5 mM ATP at 4 °C (20, 25). At the indicated time, an aliquot
was removed, and enzymatic activity was measured at saturating substrate concentrations using the coupled assay system.
Representative data from three or more determinations are
plotted as a function of time with the experimental errors indicated. A single-order decay was used to describe the data using
the program Prism (Graph Pad Software).
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L-Glutamate
L-Cysteine

ATP
GSH

Km

Vmax

Ki

mM

mol min⫺1 mg⫺1

mM

1.21 ⫾ 0.05
0.17 ⫾ 0.01
0.08 ⫾ 0.01

10.7 ⫾ 0.17
10.9 ⫾ 0.19
16.1 ⫾ 0.56
12.0 ⫾ 0.18

2.12 ⫾ 0.13

RESULTS AND DISCUSSION
Kinetic Characterization of ScGCL—Previously reported
structural and biochemical data indicate that ScGCL likely
functions as a monomer both in vitro and in vivo (24). To investigate its kinetic parameters, ScGCL was purified to homogeneity, and enzymatic activity was assessed using a coupled
enzyme system that monitors the production of ADP (11).
Apparent kinetic constants for the enzyme-catalyzed formation of ␥-glutamylcysteine were determined (Table 1) and are
comparable with those reported for other eukaryotic GCL (1,
11–13, 33). Inhibition by glutathione, a feedback inhibitor of
ScGCL, was also examined. Glutathione is a competitive inhibitor with respect to the glutamate substrate (supplemental
Fig. S1), with an apparent Ki(GSH) of 2.12 ⫾ 0.13 mM, similar to
other Group 2 GCL holoenzymes (11–13, 33).
BSO is one of the most commonly used pharmacological
inhibitors of glutathione biosynthesis, and its efficacy with
respect to inhibition of ScGCL was examined (Fig. 1). A timedependent loss of enzymatic activity was observed in the presence of Mg2⫹ and ATP at each of the BSO concentrations
VOLUME 285 • NUMBER 19 • MAY 7, 2010
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TABLE 2
Data collection and refinement statistics
The values in parentheses are for the highest resolution shell.
ScGCL-GSH
Data collection statistics
Protein Data Bank accession
code
Wavelength
Temperature (K)
Space group
Cell dimensions (Å)
Resolution, Å
Rmerge (%)
Mean I/I
Completeness (%)
Average redundancy

FIGURE 1. Time-dependent inactivation of ScGCL by the inhibitor BSO.
ScGCL was incubated with a given concentration of BSO in the presence of
Mg2⫹ and ATP at pH 8.0 and 4 °C. Relative enzymatic activity was monitored
as a function of time. The activity measurements were made in triplicate, and
the data for a given BSO concentration fit to a single exponential decay. The
curves are shown for the control (filled circles) and six experimental BSO concentrations (5 M, filled squares; 7.5 M, filled triangle; 10 M, filled inverted
triangle; 15 M, filled diamonds; 20 M, open circles; 50 M, open squares).

FIGURE 2. Ribbon representations of the crystal structures of ScGCL in complex with inhibitors. An ScGCL monomer is contained in the asymmetric unit,
and the N- and C-terminal residues are indicated. ␤-Strands are colored in yellow,
and ␣-helices are depicted in green. A, bound GSH is shown in space filling representation with carbon atoms colored in gray, oxygen atoms are in red, sulfur
atoms are in yellow, and nitrogen atoms are in blue. The glutathione-binding site
overlaps the glutamate binding site within the active site funnel. B, ADP and the
transition state analogue, phosphorylated BSO (BSO-P), are shown in space filling
representation. Phosphorus and magnesium atoms are colored in orange and
purple, respectively, with the remaining atoms colored as in A.
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Refinement statistics
Resolution, Å
Number of reflections
Rwork/Rfree (%)
Number of atoms
Protein
Ligand
Water
Average B-factors (Å2)
Protein
Ligand
Water
Root mean square deviations
from ideal
Bond lengths (Å)
Bond angles (°)
Ramachandran statistics
Favored (%)
Allowed (%)

ScGCL-BSO

3LVW

3LVV

1.54 Å
100
P43212
118.1, 118.1, 165.8
20.0-2.50
10.1 (53.3)
9.7 (3.0)
97.1 (96.1)
8.77 (8.94)

0.90 Å
100
P43212
117.9, 117.9, 165.6
50.0-2.20
5.7 (50.3)
25.4 (2.8)
100.0 (100.0)
18.7 (7.0)

20.0-2.5 (2.56-2.50)
40,046
19.9/25.1 (29.0/36.5)
5702
5476
50
176

50.0-2.20 (2.25-2.20)
59,891
18.1/23.9 (26.1/31.4)
5811
5476
58
277

46.2
56.9
43.3

37.7
33.8
38.8

0.02
1.92
95.4
99.7

0.02
1.88
96.9
99.7

tested (5 M to 50 M). A near linear dependence on the inactivation rate as a function of BSO concentration was observed
(data not shown). At 50 M BSO, ScGCL activity was reduced
nearly 10-fold in ⬃5 min. Unfortunately, reliable rate measurements above this concentration of BSO could not be made
because of the limitations of the assay. Nonetheless, BSO is
clearly a potent inhibitor of ScGCL. Previous studies of related
GCL indicated that L-buthionine-S-sulfoximine is the relevant
stereoisomer and that its enzymatic phosphorylation generates
a high affinity transition state analogue (23, 34). As discussed
below, the ScGCL-BSO structure supports these findings.
Overall Structures of ScGCL-Glutathione and ScGCL-BSO
Complexes—The structures of ScGCL in complex with either
glutathione or BSO were determined by molecular replacement
using the apo form of ScGCL as a probe (24). In the ScGCLglutathione complex, reduced glutathione was readily modeled
into the strong positive density observed within the enzyme
active site (supplemental Fig. S2). The glutamate portion of
glutathione is located at the base of the active site funnel (Fig.
2A). The cysteine moiety occupies a relatively hydrophobic
binding pocket, whereas the terminal glycine is near the outer
edge of the active site and is solvent-exposed. In the ScGCLBSO complex, the electron density supports the modeling of
phosphorylated BSO, ADP, and three Mg2⫹ ions (supplemental
Fig. S3). The adenine ring of ADP is located at the lower lip of
the active site cavity and is solvent-exposed (Fig. 2B). The phosphorylated BSO occupies a site comparable but distinct from
the glutathione-binding site, as discussed below. The overall
ScGCL-glutathione and ScGCL-BSO structures are very similar to that of ScGCL in complex with glutamate and Mg2⫹ with
an root mean square deviation for C␣ ⫽ ⬃0.2 Å (24). Refinement statistics for the final ScGCL-glutathione and ScGCLBSO models are provided in Table 2. The refined ScGCL-gluJOURNAL OF BIOLOGICAL CHEMISTRY
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the bound glutamate substrate. In
the ScGCL/Glu/Mg2⫹ structure, the
␥-carboxylate of the glutamate substrate occupies one of the coordination sites of the bound M1 Mg2⫹
(24). However, in the ScGCL-glutathione structure, the ␥-carboxylate
has been assimilated into the ␥-glutamyl peptide bond and can no longer promote Mg2⫹ binding. Glu52
and Glu96, which also coordinate the
Mg2⫹, maintain comparable positions in both structures, but Glu103
has shifted away from the M1 binding site (not shown). Loss of the M1
binding site causes the ␥-glutamyl
portion of glutathione to be shifted
⬃0.3 Å out from the base of the
active site, limiting interactions
FIGURE 3. Glutathione occupies the glutamate and presumed cysteine-binding sites of ScGCL. In the between its ␣-carboxylate and the
stereodiagram, bound glutathione is shown in ball and stick representation, and pertinent active site residues
side chain of Arg313. In addition, the
are shown in stick representation. The atoms are colored as in Fig. 2, with the exception of ScGCL carbon atoms,
which are colored green. Potential hydrogen bonds were identified in Chimera and are represented as solid M2 and M3 binding sites are not sigblack lines.
nificantly occupied in the absence of
ATP or ADP.
TABLE 3
An intriguing feature of the ␥-glutamyl-binding pocket is the
Apparent kinetic constants for C266S and C266A ScGCL
conserved cysteine residue, Cys266, which is in close proximity
Km L-Glu
V/K
Ki glutathione
Vmax
to the ␣-carboxylate of glutamate. Previously, mutation of the
mM
mol min⫺1 mg⫺1
mM
equivalent cysteine residue in T. brucei GCL to an alanine had
ScGCL
1.21 ⫾ 0.05
10.7 ⫾ 0.17
8.8
2.12 ⫾ 0.13
little effect on the specific activity or the substrate binding affinC266S
2.15 ⫾ 0.07
7.58 ⫾ 0.07
3.5
3.91 ⫾ 0.25
ity of the enzyme (35). In ScGCL, substitution of this residue
C266A
1.93 ⫾ 0.07
9.22 ⫾ 0.09
4.8
4.70 ⫾ 0.35
with either a serine (C266S) or an alanine residue (C266A) had
a modest but reproducible effect on glutamate and glutathione
tathione and ScGCL-BSO structures each have 99.7% of its binding (Table 3). For both mutants, the apparent Km(Glu) and
residues in the allowed regions of the Ramachandran plot.
the apparent Ki(GSH) increased ⬃2-fold relative to the wildThe Glutathione-binding Site Is Coincident with the Gluta- type enzyme. Studies to examine the impact of these mutations
mate- and Cysteine-binding Sites—As indicated above, reduced on overall glutathione production in S. cerevisiae are ongoing.
glutathione is a competitive inhibitor of ScGCL with respect to
Molecular Details of the L-Buthionine-S-sulfoximine-binding
glutamate and a physiologically relevant feedback inhibitor of Site—In addition to glutathione, all three families of GCL can
the enzyme (9). The ␣-carboxylate of the glutamyl moiety of be inhibited by S-alkyl-L-homocysteine sulfoximines (36). As
glutathione is positioned by hydrogen bonds with the side discussed above, BSO is a potent mechanism-based inhibitor of
chains of Tyr362 and Arg313 as well as with an ordered water ScGCL. The enzyme catalyzes the ATP-dependent phosphormolecule (Fig. 3) that in turn forms a hydrogen bond with the ylation of BSO to form BSO phosphate and ADP, which mimic
backbone carbonyl of Arg472 (not shown). Cys266 is also posi- the transition state. Phosphorylated BSO binds tightly and distioned above the plane of the carboxylate and may help orient sociates very slowly (20, 37), making this compound pharmathe bound inhibitor. The glutamyl ␣-amino group is within cologically important for development of treatments against
hydrogen bond distance of the backbone carbonyl of Cys264, the cancer and certain parasites (21, 22, 38).
Phosphorylated BSO occupies the L-glutamate and the pre␥-carboxylate of Glu52, and an ordered water molecule. The
cysteinyl ␣-amino and ␣-carbonyl groups are within hydrogen sumed L-cysteine-binding sites of ScGCL (Fig. 4A). The ␣-carbond distance of the ␥-carboxylate of Glu96 and the indole boxylate and ␣-amino groups of BSO are virtually superimposnitrogen of Trp445, respectively. An ordered water molecule able on the comparable functional groups of the glutamate
can also form a hydrogen bond with the cysteinyl ␣-carbonyl substrate (not shown). BSO is phosphorylated on the sulfoxigroup. The side chain of Arg196 is positioned to interact favor- mine nitrogen, and the S-butyl group of BSO mimics L-cysteine,
ably with the terminal carboxylate of GSH, but the glycine por- occupying a relatively hydrophobic pocket within the
tion of glutathione is poorly defined relative to the rest of the enzyme active site. Arg472 is within hydrogen bond distance
inhibitor.
of the sulfoximine oxygen and an oxygen of the newly added
As compared with the previously described ScGCL/Glu/ phosphate group and likely stabilizes the transition state. In
Mg2⫹ structure, there are several notable differences in the support of a direct role in catalysis, mutation of the equivaplacement of the ␥-glutamyl moiety of glutathione relative to lent arginine, Arg491 in T. brucei GCL, decreased enzymatic
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FIGURE 4. Analysis of the x-ray structure of the ScGCL-BSO complex reveals details of catalysis. In the
stereodiagrams, bound ligands are shown in ball and stick representation, and pertinent active site residues
are shown in stick representation. Atoms are colored as in Fig. 2, with potential hydrogen bonds represented as
solid black lines. A, phosphorylated BSO mimics the transition state. The sulfoximine nitrogen is phosphorylated
and is within hydrogen bond distance of Arg472, which may facilitate catalysis by stabilizing the transition state.
B, additional details of the ADP binding site. Examination of a previously reported ScGCL structure led to the
identification of several protein/ligand interactions (24). The 2.2 Å resolution structure of the BSO-inhibited
enzyme reveals additional contributions to ADP binding. Most notably, the imidazole ring of His94 is in close
proximity to the ␣-phosphate, and the side chain of Arg468 is within hydrogen bond distance of an ordered
water molecule that helps position the ribose ring of ADP. C, stereodiagram of Mg2⫹-binding sites in the
refined model of ScGCL in complex with phosphorylated BSO (BSO-P) and ADP. In the stereodiagram, bound
ADP and phosphorylated BSO are shown, with potential hydrogen bonds between a catalytic arginine residue,
Arg472, and phosphorylated BSO represented as solid black lines. Three Mg2⫹ ions, designated as M1, M2, and
M3, are shown as purple spheres, and dashed black lines illustrate their likely coordination (interatomic distances
of ⬍2.2 Å).

MAY 7, 2010 • VOLUME 285 • NUMBER 19

activity by 70-fold (39). Phosphorylation by ATP and subsequent tight
inhibitor-enzyme interaction is dependent on the metal ion binding
(1). The precise locations of the
three metal-binding sites are discussed below.
The crystal structures of E. coli (40)
and Brassica juncea (41) GCL in complex with alkyl sulfoximine inhibitors
have also been reported. Comparison
with the ScGCL-BSO complex reveals a dramatic conservation of active site functionality across bacteria,
plants, and nonplant eukaryotes. In
these three structures, the ␥-glutamyl-binding sites are superimposable, with the ␣-carboxylate adjacent to a conserved arginine residue
(Arg313 in ScGCL) and the ␣-amino
group within hydrogen bond distance of a bound water, the backbone carbonyl of residue 264, and
the carboxylate of Glu52 (Fig. 4A).
The proposed catalytic arginine residue, Arg472 in ScGCL, is also conserved and suggests that all three
enzymes function using a similar
mechanism.
Description of the ADP-binding
Site of ScGCL—Previously, we described the structure of ScGCL in
complex with glutamate, ADP, and
Mg2⫹ to 2.7 Å resolution (24). The
current ScGCL-BSO complex structure has been refined to significantly
higher resolution (2.2 Å) and provides additional details regarding
ADP binding (Fig. 4B). As described
previously, the 2⬘ and 3⬘ hydroxyls
of the ribose are involved in an
extended hydrogen bond network.
The oxygen of the furanose ring
forms a hydrogen bond with an
ordered water molecule that is positioned by the side chain of Arg468.
Substitution of the equivalent residue in T. brucei GCL, Arg487, with
an alanine increases the Km(ATP) ⬎
15-fold (39). The C6 amino group
and N7 nitrogen of the adenine ring
are within hydrogen bond distance of
the side chain of Gln272 and an
ordered water molecule, respectively.
Through bridging water molecules,
Thr270, Arg449, and Lys451 interact
with the pyrophosphate group of
ADP, and these residues are likely
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alanine (equivalent to Glu96 in
ScGCL) resulted in an enzyme capable of ATP hydrolysis. However, the
E93A mutant could not catalyze the
peptide bond formation between
L-glutamate and L-aminobutyrate (a
surrogate for L-cysteine), suggesting
that this glutamate residue may
instead facilitate the nucleophilic
attack of L-cysteine on the ␥-glutamylphosphate intermediate (42).
Identification of the Cysteinebinding Site of ScGCL—Attempts to
crystallize a pseudo-Michaelis complex have been unsuccessful. In each
case, the electron density for the cysteine substrate has been quite poor,
precluding the direct identification of
the cysteine-binding pocket. To overFIGURE 5. Superpositioning of the glutathione and BSO binding sites indicate the location of the cys- come this limitation, the ScGCL-gluteine-binding site. Bound ADP and BSO are shown in ball and stick representation, and pertinent active site
residues are shown in stick representation in the stereodiagram. Atoms are colored as in Fig. 2, with the tathione and ScGCL-BSO structures
exception of carbon atoms in BSO (colored in magenta). The S-butyl group of BSO and the thiol group of were superimposed, and the enviglutathione occupy a comparable hydrophobic pocket in the ScGCL active site.
ronment surrounding the cysteine
or cysteine mimic was examined
important binding determinants. In T. brucei GCL, mutation of (Fig. 5). The thiol group of glutathione and the S-butyl group of
Thr323 (Thr370 in ScGCL) to an alanine dramatically increased BSO overlay reasonably well and are located in a hydrophobic
the apparent Km for ATP (39). Interestingly, the imidazole ring pocket lined by Tyr97, Phe197, Leu200, Met258, Met262, and
of His94 moves ⬃1.4 Å toward the ADP molecule and forms Trp445. The cysteinyl amino and carbonyl groups of glutathione
hydrogen bonds with an ␣-phosphate oxygen and the ␥-car- are within hydrogen bond distance of the ␥-carboxylate of
boxylate of Glu103 (not shown). Three bound Mg2⫹ molecules Glu96 and the indole nitrogen of Trp445. These two residues
provide additional stabilizing interactions as described below.
likely orient the incoming cysteine substrate, and Glu96 may
Three Bound Mg2⫹ Ions Contribute to the Formation and facilitate the nucleophilic attack of the ␣-amino group of cysBinding of the Transition State Analogue—In the ScGCL-BSO teine on the ␥-glutamylphosphate, leading to the displacement
structure, three octahedrally coordinated Mg2⫹ ions are of the phosphate group and the formation of the ␥-glutamyl
observed (Fig. 4C). The first metal-binding site, M1, is formed peptide bond (1– 4). In addition, the guanidinium group of
by the side chain carboxylates of Glu52, Glu96, and Glu103; the Arg196 may coordinate the ␣-carboxylate of cysteine, similar to
sulfoximine nitrogen; an oxygen of the covalently attached
the arrangement seen for binding of the glycine portion of gluphosphate group; and an ordered water molecule. The M2 site
tathione (Fig. 3). In support of this assertion, mutagenesis stud268
50
470
is fashioned from the side chains of Gln , Glu , and Glu , as
ies of T. brucei GCL indicated that Arg179 (Arg196 in ScGCL) is
well as from oxygen atoms from the ␤ phosphate of ADP and
required for efficient binding of the cysteine analogue, L-amithe phosphoryl group of the transition state analogue. The M3
nobutyrate (39).
site is in contact with oxygen atoms from each of the three
Comparison of the ScGCL-BSO structure with that of E. coli
phosphate groups, the carboxylates of Glu50 and Glu103, and a
GCL
in complex with the related mechanism-based inhibitor,
2⫹
bound water molecule. This constellation of Mg -binding
(2S)-2-amino-4-[(2S)-2-carboxybutyl-(R)-sulfonimidoyl]busites facilitates the binding of ATP and positions the ␥-phosphate of ATP for in-line nucleophilic attack by the ␥-carboxy- tanoic acid (40), suggests potential differences in cysteine bindlate of the glutamate substrate. As mentioned above, Arg472 is ing. In E. coli GCL, the cysteine pocket is formed concurrently
with a conformation change in a switch loop (residues 240 –
likely a key residue in this initial step of catalysis.
2⫹
The coordination of these critical Mg ions appears to be 249). As a result, the carboxyl group of the inhibitor cysteine
300
highly conserved. A similar arrangement of active site Mg2⫹ moiety is positioned to form a hydrogen bond with Tyr , as
131
ions is observed in the equivalent E. coli GCL structure (40), well as Tyr . In ScGCL there are no significant conformadespite less than 10% sequence identity between the Group 1 tional changes in the backbone of the enzyme upon inhibitor
300
131
and 2 enzymes. Mutation of glutamate residues 55 and 100 in binding, and Tyr and Tyr of the E. coli enzyme appear to
445
196
T. brucei GCL (equivalent to Glu52 and Glu103 in ScGCL) to be functionally replaced by Trp and Arg . Interestingly, the
alanine led to a striking loss of enzyme activity, suggesting that cysteine-binding pocket of B. juncea GCL (41) more closely
Glu52 and Glu103 are indispensable for catalysis (42). Substitu- resembles that of ScGCL. However, both enzyme structures
tions at either residue likely result in the loss of Mg2⫹ binding at were determined in complex with BSO, which lacks the functhe M1 site. Interestingly, mutation of Glu93 in T. brucei GCL to tional equivalent of the ␣-carboxylate of the cysteine substrate.
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FIGURE 6. Proposed Catalytic mechanism of ScGCL. The proposed catalytic mechanism depicted is based on available biochemical and structural data for
ScGCL as discussed in the text. Arg472 of ScGCL, the residue proposed to stabilize the anionic transition state, is also shown. Additional biochemical and kinetic
studies will be required to validate the mechanism, particularly with regard to activation of the nucleophilic cysteine.

Perhaps additional conformational changes would occur if this
moiety were present.
Implications for Catalysis and Inhibitor Design—The available biochemical and structural data provide many of the
details of the catalytic mechanism of the enzyme (Fig. 6). Glutamate binds at the base of the enzyme active site with its side
chain carboxylate occupying one of the coordination sites of the
M1 Mg2⫹. The nucleophilicity of the ␥-carboxylate is likely
increased by the adjacent Mg2⫹ as well as the side chain of
Arg472. The addition of Mg2⫹/ATP leads to the formation of
two additional magnesium-binding sites, M2 and M3, which
orient the phosphate groups of ATP, placing the ␥-phosphate
in position for in-line attack by the activated glutamate substrate. This leads to the formation of a ␥-glutamyl phosphate
intermediate, which is tightly anchored in the enzyme active
MAY 7, 2010 • VOLUME 285 • NUMBER 19

site, and the eventual displacement of ADP. The incoming cysteine nucleophile is potentially activated by the side chain carboxylate of Glu96, and the developing negative charge on the
␥-carboxylate oxygen of the glutamate substrate is stabilized by
the side chain of Arg472. Collapse of the tetrahedral intermediate leads to the expulsion of the phosphate group and the formation of the ␥-glutamyl peptide bond. Additional biochemical
and mutational studies to examine this proposed mechanism
are ongoing. However, the essential features of catalysis appear
to be conserved in related enzymes such as glutamine synthetase (43, 44), glutathione synthetase (45– 47), and homoglutathione synthetase (48).
Elucidation of the detailed catalytic mechanism of GCL in
conjunction with the structural studies of the inhibited ScGCL
may lead to improved glutathione biosynthesis inhibitors. The
JOURNAL OF BIOLOGICAL CHEMISTRY

14465

S. cerevisiae Glutamate Cysteine Ligase Inhibition
alkyl sulfoximine-based inhibitors are excellent transition state
mimics that dramatically reduce enzymatic activity. Examination of the ScGCL-BSO complex suggests that additional functionalities may be engineered to increase selectivity. ScGCL and
human GCL share ⬎40% sequence identity, with nearly complete conservation of active site architecture (24), suggesting
that the insights garnered from the study of ScGCL will facilitate the development of improved therapeutics that modulate
glutathione production in mammalian systems.
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Supplemental data.

Supplemental Figure 1. To examine the mode of inhibition of glutathione, rates for the enzymecatalyzed reaction as a function of glutamate concentration were determined in the presence of fixed
concentrations of glutathione (0, 2.5, and 5.0 mM). Global analysis of the dependence of rate versus
substrate concentration indicated that glutathione was a competitive inhibitor with respect to glutamate,
with an apparent Ki (GSH) of 2.12 ± 0.13 mM.

	
  

	
  

Supplemental Figure 2. The structure of ScGCL in complex with glutathione was determined by
molecular replacement using the apo form of ScGCL as a probe. Shown in the stereodiagram is the
calculated difference map prior to the inclusion of ligands and solvent in the model. Positive and negative
peaks are contoured at 3.0 σ and shown in blue and red respectively. The final ScGCL-GSH model
corresponding to this region of the map is shown in stick representation with carbon atoms colored in
green, oxygen in red, nitrogen in blue, and sulfur in yellow. Glutathione is shown in ball and stick
representation with carbon atoms colored grey.
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Supplemental Figure 3. The structure of ScGCL in complex with phosphorylated BSO and ADP was
determined by molecular replacement using the apo form of ScGCL as a probe. Shown in the
stereodiagram is the calculated difference map prior to the inclusion of ligands and solvent in the model.
Positive and negative peaks are contoured at 3.0 σ and shown in blue and red respectively. The final
ScGCL-BSO model corresponding to this region of the map is shown in stick representation with carbon
atoms colored in green, oxygen in red, nitrogen in blue, sulfur in yellow, magnesium in magenta, and
phosphorus in orange. BSO and ADP are shown in ball and stick representation with carbon atoms
colored grey.
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